Drugs / IMIFOPLATIN
IMIFOPLATIN
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03288480 | Dec 2017 → Sep 2020 | plasma cell myeloma | Promontory Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05357196 | Apr 2020 → Aug 2022 | biliary tract cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT03409458 | Apr 2018 → Jun 2022 | non-small cell lung carcinoma | Promontory Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03439761 | Mar 2018 → May 2020 | cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02884479 | Aug 2016 → Dec 2018 | non-small cell lung carcinoma | SciClone Pharmaceuticals International (Cayman) Development Limited | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05104736 | Apr 2022 → Dec 2027 expected | thymoma, thymus cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT02266745 | Jul 2014 → Aug 2024 | castration-resistant prostate carcinoma | Promontory Therapeutics Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMIFOPLATIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802248 ↗ |
| Known as | Phosplatin's Platinum | “PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors” NCT05357196 ↗ |
| Known as | PT-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03439761 ↗ |
| Modality | Other / unclassified | “PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer” PMID 35747193 ↗ May 2022 |
| Route | Intravenous | “PT-112 intravenously” PMID 35747193 ↗ May 2022 |